Eli lilly tests how well new drug enters the body
NCT ID NCT06085482
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study in 10 healthy adults measured how much of the drug LY3502970 enters the bloodstream after being taken by mouth compared to directly into a vein. The goal was to understand the drug's absorption and breakdown in the body. Results will guide dosing for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LY3502970 (oral and intravenous)
- What this could lead to
- If successful, this study helps determine the right dose for future trials of LY3502970.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only measures drug levels, not whether the drug works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Covance Clinical Research Inc
Madison, Wisconsin, 53704, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test